Pfizer's COVID-19 vaccine trial facts suggests lengthy-time period efficacy in youth

Nov 22 (Reuters) - Pfizer Inc (PFE.N) said on Monday its COVID-19 vaccine supplied effective long-time period insurance plan towards the virus in a late-stage study carried out amongst young people aged 12 to 15 years.

A two-dose collection of the vaccine turned into 100% positive towards COVID-19, measured seven days through over 4 months after the second dose, the business stated.

A syringe is full of a dose of Pfizer's COVID-19 vaccine at a pop-up neighborhood vaccination middle at the Gateway World Christian middle in Valley flow, long island, U.S., February 23, 2021. REUTERS/Brendan McDermid

The lengthy-time period statistics will support deliberate submissions for full-regulatory approval of the vaccine in the age group in the united states and worldwide.

Pfizer and BioNTech (22UAy.DE) will searching for clearance for a 3 0 micrograms dose of the vaccine for these aged 12 and above.

The vaccine become approved for emergency use in individuals aged 12-15 years with the aid of the U.S. meals & Drug Administration in might also, and granted full approval for use in americans aged sixteen and above in August.

Register now for free of charge unlimited entry to reuters.com

Register

Reporting by Mrinalika Roy in Bengaluru; modifying via Shinjini Ganguli

Our necessities: The Thomson Reuters have faith principles.